Displaying drugs 2826 - 2850 of 3348 in total
Tozinameran
The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2...
Approved
Investigational
Matched Description: … [L26956] Fact sheets for caregivers, recipients, and healthcare providers are now available. ... Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older. ... The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Nucleic Acid-Based Vaccines …
Matched Products: … COMIRNATY 10mcg Concentrate for Dispersion for Injection ... COMIRNATY (Tris/Sucrose) 30 mcg Solution for Injection …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Nucleic Acid-Based Vaccines …
Matched Products: … COMIRNATY 10mcg Concentrate for Dispersion for Injection ... COMIRNATY (Tris/Sucrose) 30 mcg Solution for Injection …
Interferon beta-1a
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Approved
Investigational
Matched Description: … The amino acid sequence is identical to that of natural human interferon beta. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Rebif 22mcg/0.5ml solution for injection ... Rebif 44mcg/0.5ml solution for injection ... Rebif Solution for Injection in Cartridge 22mcg/0.5ml …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Rebif 22mcg/0.5ml solution for injection ... Rebif 44mcg/0.5ml solution for injection ... Rebif Solution for Injection in Cartridge 22mcg/0.5ml …
Tigecycline
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Food and Drug Administration (FDA) on June 17, 2005. ... Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion ... TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL ... TIGAR 50 (Tigecycline Powder for Solution for Infusion 50mg/Vial) …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion ... TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL ... TIGAR 50 (Tigecycline Powder for Solution for Infusion 50mg/Vial) …
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... ] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically...
Approved
Investigational
Matched Description: … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who ... By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and ... with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …
Inotuzumab ozogamicin
Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... [A20352]
Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …
Deferoxamine
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Categories: … Carboxylic Acids ... Hydroxy Acids ... Hydroxamic Acids …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …
Matched Categories: … Carboxylic Acids ... Hydroxy Acids ... Hydroxamic Acids …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …
Decitabine
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.[A215082, A215092] Among treatment options, nucleoside analogues such as...
Approved
Investigational
Matched Description: … approved by the FDA for the treatment of MDS on February 5, 2006. ... presentation, including neutropenia and thrombocytopenia. ... and related downstream therapeutic benefits. …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Antineoplastic and Immunomodulating Agents ... Nucleic Acid Synthesis Inhibitors …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Antineoplastic and Immunomodulating Agents ... Nucleic Acid Synthesis Inhibitors …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …
Daunorubicin
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Approved
Matched Description: … , used in treatment of leukemia and other neoplasms. ... A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... cytarabine and daunorubicin ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... cytarabine and daunorubicin ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …
2-amino-3-[4-hydroxy-6-oxo-3-(2-phenyl-cyclopropylimino)-cyclohexa-1,4-dienyl]-propionic acid
Experimental
Matched Name: … 2-amino-3-[4-hydroxy-6-oxo-3-(2-phenyl-cyclopropylimino)-cyclohexa-1,4-dienyl]-propionic acid …
Matched Iupac: … 2-amino-3-[(5E)-4-hydroxy-2-oxo-5-[(2-phenylcyclopropyl)imino]cyclohex-3-en-1-yl]propanoic acid …
Matched Iupac: … 2-amino-3-[(5E)-4-hydroxy-2-oxo-5-[(2-phenylcyclopropyl)imino]cyclohex-3-en-1-yl]propanoic acid …
Phosporic Acid Mono-[3,4-Dihydroxy-5-(5-Methoxy-Benzoimidazol-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester
Experimental
Matched Name: … Phosporic Acid Mono-[3,4-Dihydroxy-5-(5-Methoxy-Benzoimidazol-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester …
Matched Iupac: … {[(2R,3S,4R,5S)-3,4-dihydroxy-5-(5-methoxy-1H-1,3-benzodiazol-1-yl)oxolan-2-yl]methoxy}phosphonic acid …
Matched Iupac: … {[(2R,3S,4R,5S)-3,4-dihydroxy-5-(5-methoxy-1H-1,3-benzodiazol-1-yl)oxolan-2-yl]methoxy}phosphonic acid …
5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
Experimental
Matched Name: … 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE …
3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID
Experimental
Matched Name: … 3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID …
Matched Iupac: … 3-cyclohexyl-1-[2-(morpholin-4-yl)-2-oxoethyl]-2-phenyl-1H-indole-6-carboxylic acid …
Matched Iupac: … 3-cyclohexyl-1-[2-(morpholin-4-yl)-2-oxoethyl]-2-phenyl-1H-indole-6-carboxylic acid …
[4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID
Experimental
Matched Name: … [4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID …
Matched Iupac: … 6R,7R)-4-(4-acetamidophenyl)-3,5-dioxo-4-azatricyclo[5.2.2.0^{2,6}]undecan-1-yl]carbamoyl}oxy)acetic acid …
Matched Iupac: … 6R,7R)-4-(4-acetamidophenyl)-3,5-dioxo-4-azatricyclo[5.2.2.0^{2,6}]undecan-1-yl]carbamoyl}oxy)acetic acid …
2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID
Experimental
Matched Name: … 2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID …
Matched Iupac: … 2-{[3,5-difluoro-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid …
Matched Iupac: … 2-{[3,5-difluoro-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid …
(1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID
Experimental
Matched Name: … (1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID …
Matched Iupac: … (1S,4R,7aR)-4-butoxy-1-[(2R)-1-oxobutan-2-yl]-2,4,5,6,7,7a-hexahydro-1H-isoindole-3-carboxylic acid …
Matched Iupac: … (1S,4R,7aR)-4-butoxy-1-[(2R)-1-oxobutan-2-yl]-2,4,5,6,7,7a-hexahydro-1H-isoindole-3-carboxylic acid …
R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
Experimental
Matched Name: … R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid …
Matched Iupac: … (2R)-6-methoxy-2-{4'-methoxy-[1,1'-biphenyl]-4-sulfonamido}hex-4-ynoic acid …
Matched Iupac: … (2R)-6-methoxy-2-{4'-methoxy-[1,1'-biphenyl]-4-sulfonamido}hex-4-ynoic acid …
(R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER
Experimental
Matched Name: … (R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER …
1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
Experimental
Matched Name: … 1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE …
SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER
Experimental
Matched Name: … SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[ …
Matched Iupac: … ,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]oxy}-4-oxobutanoic acid …
Matched Iupac: … ,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]oxy}-4-oxobutanoic acid …
4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid
Experimental
Matched Name: … 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid …
Matched Iupac: … 3-({4-bromo-2-[(3R,5S)-3,5-dimethylpiperidine-1-carbonyl]phenyl}carbamoyl)propanoic acid …
Matched Iupac: … 3-({4-bromo-2-[(3R,5S)-3,5-dimethylpiperidine-1-carbonyl]phenyl}carbamoyl)propanoic acid …
3-(HYDROXY-PHENYL-PHOSPHINOYLOXY)-8-METHYL-8-AZA-BICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID METHYL ESTER
Experimental
Matched Name: … 3-(HYDROXY-PHENYL-PHOSPHINOYLOXY)-8-METHYL-8-AZA-BICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID METHYL ESTER …
Matched Iupac: … {[(1R,2R,3S,5S)-2-(methoxycarbonyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]oxy}(phenyl)phosphinic acid …
Matched Iupac: … {[(1R,2R,3S,5S)-2-(methoxycarbonyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]oxy}(phenyl)phosphinic acid …
Atosiban
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant ... admission, it is not used in that form. ... Atosiban is an inhibitor of the hormones oxytocin and vasopressin. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) ... TRACTOCILE 7.5MG/ML,SOLUTION FOR INJECTION …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) ... TRACTOCILE 7.5MG/ML,SOLUTION FOR INJECTION …
Guselkumab
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …
Emicizumab
Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017. ... Ltd. and co-developed with Roche and Genentech.[L1015] ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 30MG/ML …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 30MG/ML …
Displaying drugs 2826 - 2850 of 3348 in total